Program Goals

Gastric and Esophageal Cancer in the United States, 2013

Gastric Cancer Incidence: Geographic Differences

Gastric Adenocarcinoma: Heterogeneous Diseases

Gastric Cancer: Death Rates in the United States

Subcardial Gastric Cancer Incidence: Trends Among

Different Age Groups

Gastric Adenocarcinoma: Heterogeneous Diseases

Esophagogastric Adenocarcinomas: Pathologic

Distinctions

Pathogenesis of Esophagogastric Adenocarcinomas

Gastric Cancer: Molecular Subtypes With Distinct Expression

Profiles

Gene Signature Validated in Primary Gastric Cancers: 2

Patient Cohorts

Identifying Relevant Biologic Targets to Guide Therapeutic

Development

Significantly Mutated Genes in Whole-exome Sequencing

Studies

Exome Sequencing in GEJ and Esophageal Adenocarcinoma

Candidate Biologic Pathways in Gastric Cancer

Gastric Cancer: Single-Agent Chemotherapy

Chemotherapy Regimens for Metastatic Esophagogastric

Cancer

HER/ErbB Family in Gastric Cancer

ToGA: Phase 3 Trial of Trastuzumab in First-line

Gastric/GEJ Cancer

ToGA Primary End Point: OS

ToGA Efficacy: OS by Subgroup Analysis

HER2- Expression Frequency by Histologic Subtype

T-DM1 Structure

HER/ErbB Targeting in Gastric Cancer

Rilotumumab in First-line Gastric/GEJ Cancer: Phase 2

Trial

Rilotumumab Efficacy in ITT Population

Rilotumumab Efficacy in MET-High Population

Role of VEGF Pathway in Tumor Growth

VEGF Expression Associated With Worse Survival in Gastric

Cancer

AVAGAST: Bevacizumab in First-line Gastric/GEJ Cancer -

Phase 3 Trial

AVAGAST Primary End Point: OS

Role of VEGF Pathway in Tumor Growth

Neovascularization and VEGFR2 Expression from

Barrett’s to Esophageal Adenocarcinoma

Anti-VEGFR2 MAb in a Gastric Cancer Animal Model

REGARD: Ramucirumab Monotherapy in Second-line

Gastric/GEJ Cancer, Phase 3 Trial

REGARD: Efficacy Results

RAINBOW: Ramucirumab in Second-line Gastric/GEJ

Cancer, Phase 3 Trial

Summary and Conclusions

Summary and Conclusions (cont)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)